| Accession number;06A0389877 |
| Title;Skill to use codeine phosphate in cancer pain patients |
| Author;SUZUKI TAKAHIRO(Toukyourinkaibyouin) |
Journal Title;Pain Clinic
|
Journal Code:G0739B
|
ISSN:0388-4171
|
|
VOL.27;NO.;PAGE.S55-S58(2006)
|
| Figure&Table&Reference;FIG.2, TBL.1, REF.10 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Codeine phosphate belongs to the weak opioid analgesics of the WHO treatment model for cancer pain. About 35% of cancer patients can enjoy pain relief by step 2 treatment of which codeine phosphate plays a central role. The method causes less side-effects than morphine. Prescription of 80 to 120 mg of codeine phosphate is given each day at the beginning, and the amount can be increased up to 300 mg. Concomitant use of acetaminophen can enhance its analgesic effect. Codeine phosphate still can cause a variety of side-effects such as nausea, vomition, constipation, drowsiness, dry mouth, pruritus, and anuresis. Slow-release fentanyl patches can replace codeine phosphate when a large amount of codeine phosphate is necessary to contain pain. |
